Article
In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.
mBio - 3 Nov 2020
Datir Rawlings, Kemp Steven, El Bouzidi Kate, Mlchocova Petra, Goldstein Richard, Breuer Judy, Towers Greg J, Jolly Clare, Quiñones-Mateu Miguel E, Dakum Patrick S, Ndembi Nicaise, Gupta Ravindra K
Abstract excerpt
Protease inhibitors (PIs) are the second- and last-line therapy for the majority of HIV-infected patients worldwide. Only around 20% of individuals who fail PI regimens develop major resistance mutations in protease. We sought to explore the role of mutations in gag-pro genotypic and phenotypic changes in viruses from six Nigerian patients who failed PI-based regimens without known drug resistance-associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
